320.39
Schlusskurs vom Vortag:
$336.26
Offen:
$323.49
24-Stunden-Volumen:
123.15K
Relative Volume:
0.33
Marktkapitalisierung:
$35.13B
Einnahmen:
$3.81B
Nettoeinkommen (Verlust:
$-644.79M
KGV:
-51.34
EPS:
-6.24
Netto-Cashflow:
$-669.77M
1W Leistung:
+7.47%
1M Leistung:
+5.23%
6M Leistung:
+24.45%
1J Leistung:
+0.00%
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Firmenname
Beone Medicines Ltd Adr
Sektor
Branche
Telefon
41-616851900
Adresse
C/O BEONE MEDICINES I GMBH, BASEL
Vergleichen Sie ONC mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ONC
Beone Medicines Ltd Adr
|
320.50 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
396.08 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.63 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
566.60 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
732.50 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-07 | Eingeleitet | RBC Capital Mkts | Outperform |
2025-03-03 | Hochstufung | BofA Securities | Neutral → Buy |
2024-12-03 | Fortgesetzt | Morgan Stanley | Overweight |
2024-09-18 | Eingeleitet | JMP Securities | Mkt Outperform |
2024-02-06 | Fortgesetzt | JP Morgan | Overweight |
2023-09-12 | Eingeleitet | Macquarie | Outperform |
2023-08-17 | Eingeleitet | Jefferies | Buy |
2023-07-17 | Eingeleitet | Citigroup | Buy |
2023-06-30 | Herabstufung | Bernstein | Outperform → Mkt Perform |
2023-01-12 | Eingeleitet | Daiwa Securities | Buy |
2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
2022-10-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2022-08-09 | Fortgesetzt | JP Morgan | Overweight |
2022-03-17 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2022-02-07 | Eingeleitet | Deutsche Bank | Buy |
2021-10-12 | Eingeleitet | Bernstein | Outperform |
2021-10-06 | Hochstufung | CLSA | Underperform → Buy |
2021-03-08 | Eingeleitet | China Renaissance | Buy |
2021-03-01 | Herabstufung | CLSA | Outperform → Underperform |
2020-11-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
2020-11-06 | Herabstufung | Maxim Group | Buy → Hold |
2020-11-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
Alle ansehen
Beone Medicines Ltd Adr Aktie (ONC) Neueste Nachrichten
BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Receives $330.89 Consensus PT from Brokerages - MarketBeat
Brokerages Set BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) PT at $330.89 - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Gap UpHere's Why - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Gap Up – Here’s What Happened - Defense World
BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients - Benzinga
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Average Rating of “Buy” from Analysts - Defense World
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Average Recommendation of “Buy” from Analysts - Defense World
Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells 11,013 Shares of Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) COO Xiaobin Wu Sells 39,936 Shares - MarketBeat
Xiaobin Wu Sells 49,858 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) Sets New 52-Week HighShould You Buy? - MarketBeat
BeOne Medicines (NASDAQ:ONC) Hits New 1-Year High – What’s Next? - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap DownShould You Sell? - MarketBeat
BeOne Medicines (NASDAQ:ONC) Sets New 12-Month HighWhat's Next? - MarketBeat
BeOne Medicines DRC earnings missed by $0.04, revenue topped estimates - Investing.com India
Analysts Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) PT at $327.56 - Defense World
Chan Henry Lee Sells 920 Shares of BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Stock - MarketBeat
Insider Selling: BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Insider Sells 259 Shares of Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) Reaches New 12-Month HighHere's What Happened - MarketBeat
BeOne Medicines stock hits 52-week high at 304.0 USD - Investing.com India
Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End - Ariva
BeOne Medicines stock rises after positive EU opinion for lung cancer drug - Investing.com India
Lai Wang Sells 700 Shares of BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Stock - MarketBeat
Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock? - Yahoo Finance
BeOne Medicines (NASDAQ:ONC) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
BeOne Medicines (NASDAQ:ONC) Reaches New 52-Week High Following Analyst Upgrade - Defense World
Finanzdaten der Beone Medicines Ltd Adr-Aktie (ONC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Beone Medicines Ltd Adr-Aktie (ONC) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Wu Xiaobin | President and COO |
Aug 13 '25 |
Option Exercise |
164.24 |
49,858 |
8,188,887 |
49,858 |
Wu Xiaobin | President and COO |
Aug 14 '25 |
Option Exercise |
156.45 |
39,936 |
6,247,989 |
39,936 |
Wu Xiaobin | President and COO |
Aug 13 '25 |
Sale |
304.16 |
49,858 |
15,164,818 |
0 |
Wu Xiaobin | President and COO |
Aug 14 '25 |
Sale |
305.06 |
39,936 |
12,182,818 |
0 |
Lee Chan Henry | SVP, General Counsel |
Aug 13 '25 |
Option Exercise |
177.90 |
8,230 |
1,464,080 |
8,230 |
Lee Chan Henry | SVP, General Counsel |
Aug 13 '25 |
Sale |
300.45 |
11,013 |
3,308,877 |
0 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):